WebMD is bringing former advertisers back on board

Share this article:
David Schlanger
David Schlanger

Despite its traditionally tight-lipped earnings call, WebMD managed to share some information about its marketing plans and third-quarter results.

Among them: revenues were up almost 11.5% during the quarter compared to the same period last year, while sales and marketing expenses dipped almost 2%. The consumer and professional health company saw advertising on its public portals rise 12%, to almost $110 million, compared to around $98 million for the same period last year.

CEO David Schlanger attributed the increases to several factors, including the return of advertisers who migrated to other sites or split their ad budgets across a greater number of partners, the company's focus on being more customer-centric, and a general loosening up in the pharmaceutical advertising space as the industry prepares for an era of new drugs.

The company said increased traffic rose along with advertising dollars during the quarter across the WebMD health network, which includes consumer and professional sites such as MedicineNet, eMedicineHealth and RxList, among others.

Unique visitors rose 29% to 138 million compared to the same period last year, and page views rose 15%, to 2.95 billion. Desktop traffic rose 3% during the quarter compared to last year, fueled in part by an increase in mobile use.

The company said the relaunched WebMD app, which included enhancements such as lifestyle content and an expanded local provider search, encouraged longer, more frequent visits. The company said it launched an advertising opportunity called Medscape Brand Alerts which serves up mobile and desktop-friendly ads. The project is in its early days, but the company said the client that has signed on has been happy.

The company indicated it has also been hammering away at initiatives launched earlier in the year and announced it closed a deal last week to buy Avado, which specializes in cloud-based patient relationship management. WebMD's professional app and relaunched consumer app already allowed doctors to share instructions and information with patients in a secure environment, but public relations VP Kate Hahn tells MM&M the Avado buy will help the company expand its connectivity offerings.

Tuesday's release hints at a change of pace. The company has been wading through over a year of change that included the unexpected ouster of its CEO Cavan Redmond in May and an ad slump that forced the company to weather the year with 14% fewer employees.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...